Read our COVID-19 research and news.

Webinar Science and Life

Vaccine matters: Can we cure coronavirus?

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Vaccine matters: Can we cure coronavirus?

Recorded 12 August 2020


Top on the world’s want list right now is a coronavirus vaccine. There is plenty of speculation about how and when this might become a reality, but clear answers are scarce.
Science/AAAS, the world’s leading scientific organization and publisher of the Science family of journals, brings together experts in the field of coronavirus vaccine research to answer the public’s most pressing questions: What vaccines are being developed? When are we likely to get them? Are they safe? And most importantly, will they work? Hear from leading authorities from the U.S. National Institutes of Health, the University of Oxford, and the Vanderbilt Vaccine Research Program, with additional comments from Trevor Mundel, president of Gates Foundation Global Health Division. You cannot miss this webinar.

This webinar will last for approximately 60 minutes.

Speaker bios

Sarah Gilbert, Ph.D.

University of Oxford
Oxford, UK

Dr. Gilbert completed her undergraduate studies at the University of East Anglia and her doctoral degree at the University of Hull. Following 4 years as a research scientist at the biopharmaceutical company Delta Biotechnology, she joined the Nuffield Department of Medicine (NDM) at Oxford University in 1994 and became part of the Jenner Institute (within NDM) when it was founded in 2005. Her chief research interest is the development of viral-vectored vaccines that work by inducing strong and protective T- and B-cell responses. She leads the Jenner Institute program in influenza vaccine development and also works on vaccines for many different emerging pathogens, including Nipah, Middle East Respiratory Syndrome (MERS), Lassa fever, Crimean–Congo haemorrhagic fever, and SARS-CoV-2. Working with colleagues in the Jenner Institute research labs, the Clinical BioManufacturing Facility, and the Centre for Clinical Vaccinology and Tropical Medicine, all situated on the Old Road Campus in Oxford, she is able to take novel vaccines from design to clinical development, with a particular interest in the rapid transfer of vaccines into manufacturing and first-in-human trials. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a promising vaccine against the novel coronavirus, SARS-CoV-2.

Kizzmekia Corbett, Ph.D.

National Institute of Allergy and Infectious Diseases, NIH
Bethesda, MD

Dr. Corbett is the scientific lead for the Coronavirus Vaccines & Immunopathogenesis Team at the U.S. National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases, Vaccine Research Center (VRC). Appointed to the VRC in 2014, her work focuses on developing novel coronavirus vaccines, including mRNA-1273, a candidate vaccine against the virus that causes COVID-19 that is currently in phase 2 trials. In addition to mRNA-1273, her team boasts a portfolio that also includes universal coronavirus vaccine candidates and novel therapeutic antibodies. Additionally, Dr. Corbett spent several years working on a universal influenza vaccine that is slated for phase 1 clinical trial in the upcoming year. She has 15 years of expertise with dengue virus, respiratory syncytial virus, influenza virus, and coronaviruses. Her scientific career began at the University of Maryland, Baltimore County (UMBC), where she was a Meyerhoff Scholar and an NIH Undergraduate Scholar. She received a bachelor’s degree in biological sciences with a secondary major in sociology. She then enrolled at the University of North Carolina at Chapel Hill, where she obtained her Ph.D. in microbiology and immunology.

Kathryn M. Edwards, M.D.

Vanderbilt Vaccine Research Program
Nashville, TN

Dr. Edwards, the Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics at Vanderbilt University School of Medicine, has led many of the pivotal clinical trials of vaccines licensed in the past several decades and has played a major role in their implementation. She graduated from the University of Iowa Carver College of Medicine and completed her pediatric residency and infectious disease fellowship at Northwestern University and her postdoctoral training in immunology at Rush Medical College in Chicago. She joined the Vanderbilt Vaccine Program in 1980 and directed it for many years. She has served on multiple CDC, NIH, FDA, WHO, and Infectious Diseases Society of America (IDSA) committees. In 2006, she received the IDSA Walter E. Stamm Mentor Award for her exceptional mentoring and in 2014 was presented with the Maureen Andrew Mentoring Award from the Society for Pediatric Research. She was elected to the Institute of Medicine of the National Academy of Sciences (2008), was awarded the Maxwell Finland award for Scientific Achievement (2018), and in 2019 received the Frank H. Morriss, Jr. Leadership Award in Pediatrics. 

Jon Cohen

Jon Cohen covers infectious diseases, vaccines, CRISPR and other biomedical topics from San Diego, California.

Mr. Cohen earned his B.A. in science writing from the University of California, San Diego. He is a senior staff writer with Science and has published widely in other magazines and newspapers—including The New Yorker, The Atlantic, The New York Times Magazine, Smithsonian, Technology Review, Outside, Slate, Wired, and Surfer—as well as publishing four nonfiction books on scientific topics. He specializes in covering biomedicine with a focus on HIV/AIDS, other infectious diseases, immunology, vaccines, and global health, and has reported extensively on genetics, primate research, evolution, bioterrorism, research funding, ethics, reproductive biology, credit battles, and the media itself. He has appeared on several national TV and radio programs, including the PBS NewsHour, Today, Larry King Now, and NPR’s Fresh Air, Marketplace, and All Things Considered. Mr. Cohen has received frequent recognition for his contributions to science journalism, and his articles have twice been selected for The Best American Science and Nature Writing anthology (2008 and 2011). His books and stories have won awards from the National Association of Science Writers, the Council for the Advancement of Science Writing, the American Society for Microbiology, the American Society of Tropical Medicine and Hygiene, the Global Health Council, the Pan American Health Organization, the National Academy of Sciences, the Treatment Action Group, and the Gaia Vaccine Foundation (photo: Malcolm Linton).

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here